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The highly invasive property of glioblastoma (GBM) cells and genetic hetero-
geneity are largely responsible for tumor recurrence after the current stan-
dard-of-care treatment and thus a direct cause of death. Previously, we have
shown that intracranial interferon-beta (IFN-b) gene therapy by locally
administered adeno-associated viral vectors (AAV) successfully treats nonin-
vasive orthotopic glioblastoma models. Here, we extend these findings by
testing this approach in invasive human GBM xenograft and syngeneic
mouse models. First, we show that a single intracranial injection of AAV
encoding human IFN-b eliminates invasive human GBM8 tumors and pro-
motes long-term survival. Next, we screened five AAV-IFN-b vectors with
different promoters to drive safe expression of mouse IFN-b in the brain in
the context of syngeneic GL261 tumors. Two AAV-IFN-b vectors were
excluded due to safety concerns, but therapeutic studies with the other three
vectors showed extensive tumor cell death, activation of microglia surround-
ing the tumors, and a 56% increase in median survival of the animals treated
with AAV/P2-Int-mIFN-b vector. We also assessed the therapeutic effect of
combining AAV-IFN-b therapy with temozolomide (TMZ). As TMZ affects
DNA replication, an event that is crucial for second-strand DNA synthesis
of single-stranded AAV vectors before active transcription, we tested two
TMZ treatment regimens. Treatment with TMZ prior to AAV-IFN-b abro-
gated any benefit from the latter, while the reverse order of treatment dou-
bled the median survival compared to controls. These studies demonstrate
the therapeutic potential of intracranial AAV-IFN-b therapy in a highly
migratory GBM model as well as in a syngeneic mouse model and that com-
bination with TMZ is likely to enhance its antitumor potency.
1. Introduction
Glioblastoma is the most common primary brain
tumor (Preusser et al., 2011) as well as the most
aggressive form (WHO grade IV) of glial cell tumors
(Louis et al., 2007). The current standard-of-care treat-
ment involves surgical resection, followed by radio-
and chemotherapy with temozolomide (TMZ)
Abbreviations
AAV, adeno-associated viral vector; DAPI, 40,6-diamidino-2-phenylindole; DMSO, dimethyl sulfoxide; EGFP, enhanced green fluorescence
protein; Fluc, firefly luciferase; GBM, glioblastoma; hIFN-b, human interferon-beta; JAK/STAT, Janus kinase/signal transducers and activators
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(Hottinger et al., 2014). The tumor is characterized by
highly invasive growth, neovascularization, and high
mortality due to uncontrollable tumor recurrence. One
of the primary causes for recurrence is the inability to
surgically remove all tumor cells due to their ability to
infiltrate normal tissue and migrate long distances.
Moreover, GBM tumors develop exceptional resistance
to radiation and temozolomide. As a result of these
insidious properties of GBM, the median survival of
patients with the current standard-of-care treatment is
only 15–17 months from the time of diagnosis (Preus-
ser et al., 2015; Stupp et al., 2009). Therefore, develop-
ment of new therapies for GBM remains a high
priority.
Interferon-beta (IFN-b) is a cytokine naturally
secreted from cells upon viral infection, and it activates
in target cells ~ 300 genes through the JAK/STAT sig-
naling pathway (Schneider et al., 2014). In addition to
immunomodulation during viral infections, IFN-b is
also reported to have antitumor properties that include
direct cytostatic (Kaynor et al., 2002) and proapop-
totic (Juang et al., 2004) effects, as well as indirect
effects such as anti-angiogenesis (Streck et al., 2005;
Xiao et al., 2012), immune stimulation (Wolpert et al.,
2015; Yang et al., 2014), and drug sensitization (Kase
et al., 1993). A phase I study showed that using
repeated intravenous delivery of recombinant IFN-b as
an adjuvant to the standard-of-care treatment could
moderately improve the survival in patients without
any severe side effects (Motomura et al., 2011). How-
ever, the effectiveness of this approach is likely limited
by the short half-life of IFN-b in blood (Buchwalder
et al., 2000).
Gene therapy can potentially overcome this limita-
tion by genetically engineering cells in the target tis-
sue to produce IFN-b locally. Moreover, as IFN-b
is a secreted protein, the therapeutic effect is
expected to extend beyond the transduced cells.
Based on this concept, previously our group has
shown that local intracranial delivery of a recombi-
nant adeno-associated virus (AAV) vector driving
expression of human IFN-b from a neuron-specific
promoter can eliminate orthotopic U87 human
glioblastoma in athymic nude mouse model (Maguire
et al., 2008). This study demonstrated the principle
that AAV-mediated local IFN-b gene therapy could
be useful for glioblastoma treatment. However, U87
tumor is noninvasive in nature unlike glioblastoma
in patients where infiltration and migration are
important features that contribute significantly to
therapeutic failure. Therefore, in the current study
we first sought to test the intracranial AAVrh8-IFN-
b-based therapeutic approach in a highly invasive
human glioblastoma model (GBM8) (Wakimoto
et al., 2009) implanted in athymic nude mice.
A limitation of therapeutic studies with human IFN-
b in xenograft GBM models is that they have to be
conducted in immuno-deficient athymic nude mice
where human IFN-b does not interact with mouse
IFN-b receptors (Harari et al., 2014). The complex
interaction of IFN-b with the immune system and
tumor cells will determine the therapeutic outcome of
an AAV-IFN-b strategy. Therefore, in a second set of
experiments we tested the therapeutic efficacy of an
AAV-IFN-b encoding the mouse cytokine in an ortho-
topic syngeneic mouse glioblastoma (GL261) model in
normal C57BL/6J mice. Finally, we compared the
therapeutic efficacy of AAV-IFN-b combined with the
standard-of-care chemotherapeutic drug TMZ treat-
ment in relation to chemotherapy alone.
2. Materials and methods
2.1. Cell culture, WST-1 assay, and LDH assay
Human GBM8 glioblastoma cells (Wakimoto et al.,
2009) were a kind gift from Dr. Samuel Rabkin (Mas-
sachusetts General Hospital, Boston, MA, USA).
GBM8-Fluc cells that constitutively express firefly luci-
ferase were generated and grown as previously
described (GuhaSarkar et al., 2016).
GL261 cells were purchased from the National Can-
cer Institute-Frederick, Bethesda, MD, USA. The cells
were grown in Dulbecco’s modified Eagle’s medium
(Gibco, Grand Island, NY, USA) supplemented with
10% fetal bovine serum (Sigma-Aldrich, St Louis,
MO, USA), 1% penicillin–streptomycin (Gibco), and
1% L-glutamine (Mediatech, Manassas, VA, USA).
WST-1 assays (Roche, Westborough, MA, USA)
were used to evaluate cell proliferation in the presence
of recombinant human IFN-b (hIFN-b) protein or
infection with AAV9/CB-mIFN-b for GBM8-Fluc or
GL261 cells, respectively. Adherent GBM8-Fluc cells
were cultured in plates precoated with laminin by
overnight incubation with 10 lgmL1 laminin (Invit-
rogen, Carlsbad, CA, USA) at 37 °C. Studies were
conducted in 12-well dishes seeded with 200 000 cells
per well 1 day before initiating the studies. The follow-
ing day, the growth medium was replaced with fresh
growth medium premixed with 100 IU of recombinant
hIFN-b protein (PeproTech, Rocky Hill, NJ, USA)
supplemented every 72 h for GBM8 cells, or AAV9/
CB-mIFN-b vector (at a dose of 100 000 vg per cell)
for GL261 cells.
LDH assays (Roche) were used to assess cell
death or cytotoxicity after recombinant hIFN-b
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protein treatment to GBM8-Fluc cells. Culturing of
GBM8-Fluc cells, plating, and IFN-b treatments for
this assay were similar to WST-1 study. This time
we tested the effect of treatment both with short-
term (every 3 h for 12 h) and long-term (every
3 days for 9 days) exposure to hIFN-b. To make
sure that the assay is working, we treated the cells
with 1% Triton X-100 (BDH Chemicals, Westch-
ester, PA, USA) as a positive control for the short-
term study. This cytotoxicity assay was performed
in both the presence and absence of the growth fac-
tors in the media for the short-term study and with
growth factors for the long-term study.
2.2. Animals
Six- to eight-week-old male athymic nude mice were
obtained from the National Cancer Institute for the
xenograft study with GBM8 cells. For the syngeneic
tumor study, 6- to 8-week-old male C57BL/6J mice
were used (Jackson Laboratory, Bar Harbor, ME,
USA). The humane endpoint for the animals was
defined as the loss of > 15% of maximum body weight
or appearance of any neurological symptoms (such as
hunched posture). All animal studies were approved
by the Institutional Animal Care and Use Committee
at the University of Massachusetts Medical School.
2.3. Tumor grafting in mouse brain
On the day of surgery, GBM8-Fluc cells were dissoci-
ated and prepared as a single-cell suspension in sterile
Dulbecco’s phosphate-buffered saline (PBS) (Gibco),
and 50 000 cells in 1 lL were injected stereotaxically
into the left striatum of athymic nude mice at
0.2 lLmin1. GL261 tumors were generated by
stereotaxic injection of 10 000 GL261 cells in 1 lL
into the left striatum of C57BL/6 mice using the same
injection parameters. The stereotaxic coordinates for
tumor implantation from bregma were as follows (in
mm): AP: +0.5; ML: 2.0 (left); and DV from brain
surface: 2.5.
2.4. AAV vector design, production, and delivery
For the xenograft study, AAVrh8/CBA-hIFN-b and
a corresponding AAVrh8 vector without a transgene
(empty vector) were used, as previously described
(Maguire et al., 2008). For the studies in the syn-
geneic mouse tumor model, the following vectors
were used: AAV9/CB-mIFN-b, AAV9/P2-Int-mIFN-
b, AAV9/hSyn1-mIFN-b, AAV9/Ple32-mIFN-b, and
AAV9/Ple88-mIFN-b. These vectors contained
mouse IFN-b cDNA under the CB, P2-Int, human
Syn1, Ple32, or Ple88 promoters, respectively, and
were packaged as AAV9. Detail descriptions of the
promoters are provided in Table S1. For the GFP
reporter study, the vectors used were as follows:
AAV9/P2-Int-EGFP and AAV9/Ple88-EGFP encod-
ing the enhanced green fluorescence (GFP) protein.
AAV vectors were delivered at the same site in the
left striatum where tumors were implanted previ-
ously using the same stereotaxic coordinates and
same flow rate of injection mentioned for the tumor
grafting. The volume of injections for all AAV vec-
tors was 2 lL, and PBS was used as the dilution
medium.
2.5. Temozolomide treatment
Temozolomide (Selleckchem, Houston, TX, USA)
powder was reconstituted in dimethyl sulfoxide
(DMSO) (Thermo Fisher Scientific, Fair Lawn, NJ,
USA) at a concentration of 20 mgmL1 and stored
frozen at 80 °C as single-use aliquots. Mice received
2.5 mg daily for five consecutive days from day 4 to
day 8 (regimen 1) or day 10 to day 14 (regimen 2)
after GL261 tumor implantation.
2.6. Live bioluminescence imaging
Live bioluminescence imaging of tumor-associated
firefly luciferase (Fluc) activity was performed using a
Xenogen IVIS-100 imaging system (PerkinElmer,
Waltham, MA, USA) 3 min after intraperitoneal injec-
tion of 4.5 mg D-luciferin in 150 lL of sterile PBS.
Images were acquired using LIVING IMAGE software
(PerkinElmer).
2.7. Tissue RNA preparation and quantification of
mIFN-b transcripts
Total RNA was isolated using TRIzol (Invitrogen)
reagent and Direct-zol RNA MiniPrep kit (Zymo
Research Corporation, Irvine, CA, USA) from 3-mm
striatal punches from the injected side of the brain.
RNA was treated with TURBO DNase (Ambion, Fos-
ter City, CA, USA) for 30 min at 37 °C before using
it for reverse transcription reaction with High-Capacity
RNA-to-cDNA kit (Applied Biosystems, Foster City,
CA, USA). RT-qPCR was performed using TaqMan
gene Expression Master Mix (Applied Biosystems)
with the following primers (IDT, Coralville, IA, USA)
and probe (TIB Molbiol, Adelphia, NJ, USA) for
bovine growth hormone polyadenylation signal
(BGHpA) present on AAV transgene.
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Forward primer sequence: 50-CCTCGACTGTGCC
TTCTAG-30;




Mouse HPRT1 gene expression was used as an
internal control to normalize all values (Assay ID:
Mm00446968_m1; Applied Biosystems).
2.8. Mouse IFN-b protein extraction from brain
and detection by western blot
Mouse brain punches (3 mm diameter) were taken
from the injection sites 1 month post-AAV9/mIFN-b
injections. Tissues were collected into microcentrifuge
tubes and frozen immediately in a dry ice/2-methyl
butane bath and stored at 80 °C. Protein extracts
for western blot were prepared from frozen tissue
pieces by bead lysis using T-PER tissue lysis buffer
(Thermo Fisher Scientific) supplemented with cOm-
plete Mini Protease Inhibitor cocktail (Roche, Indi-
anapolis, IN, USA). Tissue lysates were centrifuged
at 12 000 g for 1 min at 4 °C and total protein in
the supernatant quantified using the Bradford pro-
tein assay (Bio-Rad, Hercules, CA, USA). Total pro-
tein (60 lg) was separated by polyacrylamide gel
electrophoresis in 4–20% Mini-PROTEAN TGX gels
(Bio-Rad) and transferred to nitrocellulose mem-
brane. Primary antibodies used in western blots were
as follows: rabbit polyclonal anti-mouse IFN-b anti-
body (AB2215; EMD Millipore, Billerica, MA, USA,
dilution 1 : 250) and mouse monoclonal anti-b-actin
antibody (Sigma-Aldrich, dilution 1 : 1000). Second-
ary antibodies used were as follows: horse radish
peroxidase (HRP)-conjugated ECL donkey anti-
rabbit IgG (GE Healthcare, Westborough, MA,
USA, dilution 1 : 10 000) and HRP-conjugated ECL
sheep anti-mouse IgG (GE Healthcare, dilution
1 : 10 000). Pierce ECL Western Blotting Substrate
(Thermo Fisher Scientific) was used for detection, and
X-ray films were exposed for 30 min and 30 s for mIFN-
b and b-actin detection, respectively. Two independent
protein preparations were used for each sample.
2.9. Histological analysis
For histological analysis, we used 20-lm cryosections
(Fig. 1) or 5-lm paraffin sections (Figs 2–5) of mouse
brains. Mayer’s hematoxylin (Sigma-Aldrich) and eosin
Y alcoholic solution with phloxine (Sigma-Aldrich)
were used for histological staining. The primary
antibodies used for immunohistochemistry were rabbit
monoclonal anti-GFP (G10362; Invitrogen, dilution
1 : 1000), rabbit polyclonal anti-Iba1 (019-19741;
Wako, Cape Charles, VA, USA, dilution 1 : 500), and
rabbit polyclonal anti-CD3 (Abcam, Cambridge, MA,
USA, dilution 1 : 100). Biotinylated goat anti-rabbit
IgG (Vector Labs, Burlingame, CA, USA, dilution
1 : 1000) was used as secondary antibody. VECTAS-
TAIN Elite ABC Kit (Vector Labs) and DAB substrate
kit (Vector Labs) were used for immunohistochemical
detection. For immunofluorescence staining, the pri-
mary antibodies used were rabbit polyclonal anti-GFP
(A11122; Invitrogen, dilution 1 : 1000) and mouse
monoclonal anti-NeuN (MAB377; EMD Millipore,
1 : 500). The secondary antibodies used were Alexa
Fluor 488-conjugated F(ab0)2 goat anti-rabbit IgG
(A-11070; Thermo Fisher Scientific, dilution 1 : 1000)
and Alexa Fluor 594 goat anti-mouse (A-11020; Thermo
Fisher Scientific, dilution 1 : 2000). Sections were coun-
terstained with nuclear stain 40,6-diamidino-2-phenylin-
dole (DAPI) (Thermo Fisher Scientific, 0.1 lgmL1).
Three or four different brains and three individual sec-
tions from each brain were analyzed for all histological
data, and the images shown are representative. Leica
DM5500 B microscope (Leica Microsystems, Buffalo
Grove, IL, USA) was used for all image acquisitions,
and Adobe Photoshop CS6 (Adobe Systems, San Jose,
CA, USA) was used for image processing.
2.10. Graphs and statistical analysis
Graphs and statistical analyses were performed in
PRISM 6 (GraphPad Software, La Jolla, CA, USA).
Kaplan–Meier survival curves were analyzed using
Mantel–Cox log-rank tests. Unpaired two-tailed t-test
was performed for statistical analysis of the bar
graphs. P values were indicated as *P < 0.05,
**P < 0.01, and ***P < 0.001.
3. Results
3.1. Single intracranial injection of AAV-hIFN-b
successfully treats tumors in invasive
glioblastoma xenograft model
Treatment of GBM8-Fluc cells in culture with recombi-
nant human IFN-b over a 9-day period resulted in signifi-
cant inhibition of proliferation by day 6 (Fig. 1A).
However, we did not see any significant cell death for
IFN-b-treated cells in this period (Fig. S1). Next, we
tested the therapeutic efficacy of intracranial administra-
tion of 3 9 1010 gc AAVrh8/CBA-hIFN-b in GBM8
tumor-bearing mice at 2, 3, or 4 weeks after tumor
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implantation (Fig. 1B). Tumor growth was assessed
weekly by live imaging of tumor-associated biolumines-
cence signal (TABS) starting at 5 weeks after tumor
implantation, a time when there was no detectable TABS
in week 2 treatment group animals, whereas all animals in
the empty vector control group showed high signals. In
week 3 and week 4 treatment groups, there was con-
siderable variability in TABS among animals (Fig. 1C).
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An 8-month study showed that 83.3% of mice in the
week 2 group survived until the experimental endpoint,
whereas all animals in the control groups (untreated
and empty vector) were euthanized on or before day
50 after tumor implantation with median survivals of
47–49 days. Consistent with the variability in TABS, a
smaller percentage of animals in week 3 (33.3%) and
week 4 (40%) groups survived until the experimental
endpoint with median survivals of 66 and 110 days,
respectively (Fig. 1D). Histological analysis of brains
at the endpoint revealed diffuse ipsilateral tumors and
long-distance migration to the contralateral hemisphere
in animals from the control groups. In contrast, there
was no evidence of tumors in animals that survived to
the experimental endpoint at 8 months. Animals from
week 3 and week 4 treatment groups that reached the
humane endpoint showed tumors of varying sizes and
spread. Of note is that in several animals large tumors
were found in the contralateral hemisphere and these
appeared less diffuse than tumors in the control
groups (Fig. 1E).
3.2. Single intracranial injection of AAV-mIFN-b
improves survival of normal mice with syngeneic
GL261 brain tumors
Next, we tested the therapeutic efficacy of intracranial
AAV-IFN-b gene therapy in the GL261 brain tumor
model in C57BL/6J mice. For these studies, all AAV
vectors encoding mouse IFN-b (mIFN-b) as the human
cytokine do not have antiproliferative properties in
mouse tumors (Harari et al., 2014). Transduction of
GL261 cells in culture with AAV9-mIFN-b resulted in
significant inhibition of proliferation by day 6 compared
to both PBS and AAV9-EGFP controls (Fig. 2A).
As IFN-b is a potent cytokine, we tested five differ-
ent AAV9 vectors encoding mIFN-b under different
promoters (Table S1) for safety and antitumor effect
in a pretreatment experimental model. AAV9 vectors
(5 9 109 gc) were injected in the striatum 2 weeks
prior to injection of GL261 tumor cells in the same
stereotaxic coordinates and the effect on survival ana-
lyzed. Kaplan–Meier survival curves (Fig. S2) showed
that groups treated with AAV9 vectors carrying Ple32
and CB promoters had lower median survival
(21 days) than the PBS control group (25 days), sug-
gestive of toxicity. Hence, these two vectors were
excluded from further therapeutic studies. The other
three groups treated with AAV9 vectors carrying pro-
moters P2-Int, hSyn1, and Ple88 showed small
improvements in median survival to 31, 31, and
33 days, respectively (Fig. S2). These three vectors
were selected for further studies.
Tumor-bearing mice received intrastriatal injections
of the AAV9-mIFN-b vectors selected above
(3 9 1010 gc), or PBS, at the site of GL261 tumor cell
implantation. Kaplan–Meier survival curves showed
moderate but statistically significant improvements in
survival for all AAV treatment groups. Median sur-
vivals were improved to 31, 32, and 39 days for the
Ple88, hSyn1, and P2-Int groups, respectively, from
25 days in PBS control (Fig. 2B). Histological analysis
revealed extensive cell death in the tumor center in AAV
treatment groups unlike the more uniform appearance
of tumors in the PBS control group (Fig. 2C).
3.3. Transgenes are expressed in brain after
AAV9 gene delivery to mouse striatum
The therapeutic effect of AAV9-mIFN-b vectors was
likely mediated by expression of IFN-b as its mRNA
(Fig. 3A) and protein (Fig. 3B) levels were elevated in
the injected striatum compared to PBS controls. The
hSyn1 promoter is known to drive neuron-specific
transgene expression in mouse brain after AAV-
mediated delivery (Lukashchuk et al., 2016). Striatal
injection of AAV9/P2-Int-EGFP and AAV9/Ple88-
EGFP vectors (3 9 1010 gc) resulted in efficient distri-
bution and transduction of cells of primarily neuronal
phenotype (Figs 3C and S3).
Fig. 1. Local intracranial injection of AAVrh8/CBA-hIFN-b improves survival of GBM8-Fluc-implanted athymic nude mice. (A) WST-1 assay
shows the effect of recombinant hIFN-b protein treatment on GBM8-Fluc cell proliferation in culture. GBM8-Fluc cells were treated with
100 IU recombinant hIFN-b every 72 h. Unpaired Student’s t-test results: *P < 0.05; **P < 0.01. (B) Schematic diagram showing timing of
tumor implantation, AAVrh8/CBA-hIFN-b treatment, and bioluminescence imaging. (C) Representative images of tumor-associated
bioluminescence signal in live mice from different groups. Two randomly chosen animals from each treatment group are shown. (D)
Kaplan–Meier survival curves for treatment at different time-points after tumor implantation: week 2 (red curve), week 3 (green curve), and
week 4 (blue curve). Empty vector control (black curve) was injected at week 2. Another control group was left untreated (orange curve).
Number of animals per group (n) = 5 for untreated and week 3 treatment groups. For all other groups, n = 6. Log-rank test (compared to
empty vector group): *P < 0.05; ***P < 0.001. (E) Representative rostral–caudal brain sections at the experimental endpoint for week 2
treatment (day 244), and humane endpoints for empty vector (day 44) and week 4 treatment (day 65). Abbreviations: wk, weeks post-tumor
implantation; d, days post-tumor implantation.
185Molecular Oncology 11 (2017) 180–193 ª 2016 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.
D. GuhaSarkar et al. Intracranial AAV-IFN-b treatment of orthotopic glioblastoma
Fig. 2. Local intracranial injection of AAV9-mIFN-b improves survival of GL261 tumor-bearing mice. (A) WST-1 assay shows the effect of
AAV9/CB-mIFN-b treatment (MOI = 105) on GL261 cell proliferation in culture. Controls were treated with AAV9/CB-EGFP vector or PBS.
Unpaired Student’s t-test results: ***P < 0.001. (B) Experimental design (top) and Kaplan–Meier survival curves (bottom) for therapeutic
efficacy study in GL261-implanted C57BL/6J mice treated with three different AAV9 vectors expressing mIFN-b under different promoters:
P2-Int (red curve), hSyn1 (blue curve), and Ple88 (green curve). PBS was injected as control (black curve). Number of animals per group
(n) = 5. Log-rank test results: *P < 0.05; **P < 0.01. (C) Representative pictures of tumors at the humane endpoints from different vector
treatment groups and PBS control. Asterisks indicate the site of extensive cell death after treatment. Scale bar represents 500 lm.
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3.4. Histological analysis of microglia/
macrophage activation and T-cell infiltration in
tumor-bearing brain after AAV9/P2-Int-mIFN-b
treatment
As tumor-associated microglia/macrophages (TAMs)
and T cells are important components of the immune
system shown to influence brain tumor growth
(Kmiecik et al., 2013; Li and Graeber, 2012; See et al.,
2015), we analyzed the presence of these cells in
tumor-bearing brains after treatment with AAV9/P2-
Int-mIFN-b vector, as the corresponding treatment
cohort had the longest median survival (Fig. 2B). Acti-
vated TAMs (amoeboid Iba1+ cells) were readily
apparent in all tumor-implanted brains, both AAV-
treated and PBS-treated, compared to brains without
Fig. 3. Transgene expression in brain after AAV9-mediated intracranial delivery in mouse striatum. (A) RT-qPCR analysis of AAV vector-
derived transgene mRNA. Punches were taken 1 month after intrastriatal injection of 3 9 1010 gc of AAV9 vectors encoding mIFN-b gene
under P2-Int, hSyn1, or Ple88 promoters. (B) Western blot analysis of mIFN-b expression from striatal punches of injected sites as
described in A. (C) Distribution of EGFP-positive cells in the striatum 1 month after injection of AAV9-P2-Int-EGFP or AAV9-Ple88-EGFP
vectors. An AAV9/P2-int-mIFN-b-injected brain was used as a no-EGFP control. Corresponding magnified views of the areas marked with
black boxes in the left panel are shown on the right. Scale bars represent 50 lm.
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tumor, where we saw only resting Iba1+ cells (fine
ramified structure). However, in AAV9/P2-Int-mIFN-
b-treated brains there were noticeably higher numbers
of activated TAMs in the brain around the tumor bor-
der compared to the PBS-treated control (Fig. 4A).
CD3+ T cells were present in AAV-treated brains in
normal brain parenchyma near the tumor border at an
early time-point (day 26 after tumor implantation) in
contrast to PBS-treated controls where there was no
evidence of CD3+ cells. However, CD3+ T cells were
no longer found at the humane endpoint (day 38) for
the AAV-treated group (Fig. 4B). Interestingly, we
observed that at the time of T-cell infiltration (day 26),
the tumor size in AAV-treated brains was markedly
smaller when compared to PBS-treated control and the
treated tumors already showed considerable amount of
cell death at the center (Fig. 4C).
3.5. AAV9/P2-Int-mIFN-b and temozolomide
combination therapy improves survival over each
treatment modality alone
Temozolomide (TMZ) is the standard-of-care
chemotherapeutic drug used in conjunction with radia-
tion following neurosurgical resection. Here, we sought
to determine whether the combination of AAV9/P2-Int-
mIFN-b with TMZ has increased potency compared to
each therapy alone. However, as TMZ compromises
DNA replication, which is necessary for conversion of
AAV to a transcriptionally active double-stranded gen-
ome, it is possible that the combination would compro-
mise the therapeutic effect of IFN-b gene therapy. To
assess this possibility, two regimens were tested where
GL261-implanted animals were treated with TMZ for
five consecutive days starting 3 days before (regimen 1)
Fig. 4. Histological analysis of mouse brains treated with AAV9/P2-Int-mIFN-b. Representative brain sections immune-stained with
antibodies to (A) Iba1 or (B) CD3 to detect the presence of tumor-associated microglia/macrophages and T cells, respectively. White
discontinuous lines in (A) indicate the border between tumor and normal brain. The letter ‘T’ indicates the tumor side of the border. Arrows
point to the Iba1+ cells. Arrowheads in (B) point to the CD3+ cells. (C) Corresponding hematoxylin–eosin-stained sections. Asterisks indicate
the site of extensive cell death after treatment. (A–C) Top row shows brains that received PBS in place of tumor cells and treatment.
Bottom three rows show animal brains that received PBS or AAV9/P2-Int-mIFN-b 7 days after tumor implantation, and collected at day 26,
or at the respective humane endpoint. Scale bars represent 100 lm. Abbreviation: d, days post-tumor implantation.
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or 3 days after (regimen 2) AAV treatment. Two doses
(1 9 1010 or 3 9 1010 gc) of AAV9/P2-int-mIFN-b
were tested. Regimen 1 provided no survival benefit
compared to either modality alone (Fig. 5A), while the
combination of TMZ with AAV in regimen 2 provided
a significant improvement in survival (Fig. 5B). In
Fig. 5. Combination of AAV9/P2-Int-mIFN-b with temozolomide improves therapeutic efficacy. (A-B) Schematic diagram of experimental
paradigms (top) and Kaplan–Meier survival curves (bottom) for the therapeutic efficacy study of AAV9/P2-Int-mIFN-b and temozolomide
(TMZ) combined treatment. Two TMZ regimens were tested: daily 2.5 mg TMZ administered from day 4 to day 8 in regimen 1 (reg1) or day
10 to day 14 in regimen 2 (reg2). Diluted DMSO (1 : 3 in PBS) was used as control for TMZ and PBS was used as control for AAV
treatment. The survival curve for the (PBS + diluted DMSO) control group (black line) was used for comparison both in A and in B. Log-rank
test results: *P < 0.05; **P < 0.01. Animals per group (n) = 5. (C) Hematoxylin–eosin staining of GL261 tumor-bearing mouse brains at the
humane endpoints. Asterisks indicate the site of extensive cell death after treatment. (D) Images show brain sections stained for the
microglia marker Iba1. White discontinuous line indicates the border between tumor and normal tissue. The letter ‘T’ indicates the tumor
location. Scale bars represent 100 lm. Abbreviations: reg, TMZ dose regimen; d, days post-tumor implantation.
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regimen 2, the median survival for TMZ or AAV9/P2-
Int-mIFN-b (at 3 9 1010 gc) alone was 34 and 38 days,
respectively, while the median survival for the combina-
tion therapy was 41 and 55 days for AAV doses of
1 9 1010 and 3 9 1010 gc, respectively. Overall, the
median survival for combination therapy with TMZ
regimen 2 and AAV9/P2-Int-mIFN-b at 3 9 1010 gc
more than doubled the median survival of the
PBS + DMSO control group, where it was only
26 days.
Histopathological analysis of the brains in the
TMZ/AAV combination groups showed extensive cell
death at the tumor center compared to TMZ-only-
treated groups (Fig. 5C). In addition, there were con-
siderably more activated TAMs (amoeboid Iba1+ cells)
in the brain around the tumor in the combination
treatment groups compared to the ones treated with
TMZ alone (Fig. 5D).
4. Discussion
Studies in the past have demonstrated the antitumor
potential of IFN-b protein on glioblastoma ranging
from cell culture studies (Happold et al., 2014) to clini-
cal trials (Motomura et al., 2011). But the short half-
life (Buchwalder et al., 2000) of recombinant IFN-b is
a major limiting factor in achieving greater therapeutic
benefit. Gene therapy is an attractive approach to
overcome this limitation. Several studies from our
group (Maguire et al., 2008; Meijer et al., 2009) and
others (Denbo et al., 2011; Streck et al., 2006) have
demonstrated the potential of IFN-b gene therapy for
glioblastoma. But none of these studies has tested this
approach in an orthotopic glioblastoma model that is
truly invasive in nature. The current study, to the best
of our knowledge, is the first that shows that local
IFN-b gene therapy can effectively treat highly inva-
sive human glioblastoma in an orthotopic mouse xeno-
graft model. This is also the first study where long-
term survival benefit was achieved in a highly invasive
glioblastoma model using only a single local intracra-
nial injection of AAV vectors. An interesting finding
was that in week 3 and week 4, treated animals that
succumbed to disease progression had tumors with dis-
tinct borders unlike the diffuse pattern observed for
these invasive GBM8 tumors in PBS-treated control
animals. This suggests that IFN-b may have antimi-
gratory properties, but further studies are necessary to
further investigate this unexpected finding.
In the current study, we also assessed the therapeu-
tic potential of AAV-IFN-b gene therapy in a syn-
geneic mouse glioblastoma model. As IFN-b interacts
with its receptor in a species-specific manner for its
antiproliferation effect (Harari et al., 2014), we used
mouse IFN-b for treatment of this mouse tumor.
While AAVrh8 was used for the xenograft study to be
consistent with our previous study with xenograft
orthotopic study (Maguire et al., 2008), we used
AAV9 vectors in the syngeneic study as AAV9 is more
clinically relevant than AAVrh8 as there are several
ongoing clinical trials for neurological diseases using
AAV9 (ClinicalTrials.gov identifiers: NCT02122952,
NCT02725580, NCT02240407). We tested different
promoters that were expected to be active in different
cell types in the brain to design an AAV9-mIFN-b
vector for optimal expression of IFN-b. This was criti-
cal to reduce the risk of possible detrimental side
effects related to continuous expression of IFN-b in
the brain, as became apparent for a subset of AAV
vectors where survival of treated animals was shorter
than that of PBS-treated controls (Fig. S2). Nonethe-
less, the screening process identified several AAV9 vec-
tor designs that provided moderate survival benefit,
and the histological appearance of tumors in AAV
treatment groups with large centers devoid of cells
indicates that mIFN-b expression had a potent biologi-
cal effect on the tumor. In these studies, mice reached
the humane endpoint because of rapid body weight
loss and appearance of neurological symptoms. In con-
trol animals, this was likely caused by the large tumor
masses that occupy a substantial fraction of the ipsilat-
eral hemisphere. However, the reason behind AAV-
treated animals reaching humane endpoint may have
been caused by the residual tumor mass or by an
inflammatory response triggered either by a direct
effect of mIFN-b on microglia or by the tumor cell
death. Apparently exposure of microglia to IFN-b trig-
gers the secretion of neuroinflammatory mediators
(TNF-a, IL-1-b, IL-6, or nitric oxide) (Kawanokuchi
et al., 2004). This can potentially have detrimental
effects on the nervous system in a mouse, which in
turn could result in body weight loss in the long term
and thus forcing humane euthanasia.
The notion that an inflammatory response may have
been triggered by AAV-mIFN-b treatment is supported
by the substantial increase in activated microglia (amoe-
boid Iba1+ cells) around tumors in treatment groups
compared to controls. Nonetheless, gliomas are also
known to secrete chemoattractant molecules (e.g.,
CSF1, SDF1, CX3CL1) that attract microglia/macro-
phages (Hambardzumyan et al., 2016). Presently, it is
unknown how the increased numbers of tumor-asso-
ciated microglia/macrophages (TAMs) associated with
AAV-mIFN-b treatment affected tumor growth.
Finally, we have also shown that AAV-mIFN-b gene
therapy can be applied in tandem with the current
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standard care temozolomide treatment to significantly
improve the survival benefit. Interestingly, we have
observed that the temporal order of temozolomide and
AAV treatment is an important factor in determining
the added benefit from the combined therapy. We found
that starting temozolomide prior to AAV abolished the
potentiated therapeutic benefit observed when temo-
zolomide was started 3 days after AAV injection
(Fig. 5A,B). Although we did not study the mechanistic
details, one possible reason for this observation could
be that DNA alkylation caused by temozolomide inter-
feres with the DNA synthesis necessary to generate
transcriptionally active double-stranded AAV genomes
(McCarty, 2008). Presently, we are unable to exclude
the possibility that TMZ may inhibit any number of the
cellular pathways necessary for productive AAV gene
expression. While further studies are needed to uncover
the exact mechanism, the potential effect of TMZ on
AAV gene transfer to CNS is an important finding for
any future therapies involving AAV gene delivery and
DNA-alkylating agents. The detrimental effect of TMZ
on AAV gene therapy may not be a significant limita-
tion in clinical practice as chemotherapy usually starts
4 weeks after surgery in patients with glioblastoma
(Mao et al., 2015; Stupp et al., 2005), and thus, local
injection of AAV-IFN-b vectors in the brain tissue
immediately after surgical resection of tumors would be
a viable option.
The current study shows the intracranial AAV-IFN-
b gene therapy approach to be effective in two differ-
ent aggressive glioblastoma models. It has been suc-
cessful to provide long-term survival in the invasive
human GBM xenograft model and more than doubled
the median survival in the syngeneic GL261 mouse
tumor model when used in combination with temo-
zolomide therapy. Considering that the median sur-
vival of patients with glioblastoma is very short with
the current standard-of-care treatment, the therapeutic
benefit shown for intracranial AAV-IFN-b therapy
would be a significant improvement. Moreover, the
therapeutic impact of this gene therapy approach may
be further refined by fine-tuning IFN-b expression
using transcriptional and post-transcriptional regula-
tion to make transgene expression more specific for
tumor cells or tumor microenvironment (Ruan et al.,
2001; Wu et al., 2009; Yawata et al., 2011). Use of
switchable promoters (Chtarto et al., 2003) could be
an option to avoid possible toxicity from long-term
continuous expression of IFN-b, and cotreatment of
phosphodiesterase inhibitors could potentially mini-
mize the possible neuroinflammatory side effects of
IFN-b treatment (Kawanokuchi et al., 2004).
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